Timothy Yap

Timothy Yap

Company: MD Anderson Cancer Centre

Job title: Associate Professor, Investigational Cancer Therapeutics


Development of PARP Inhibitor Combinations 9:00 am

• PARP inhibitors are FDA approved in multiple indications as monotherapy • However, issues of intrinsic and acquired resistance still hamper patient benefit • The development of PARP inhibitor combinations is a rational approach to deepen and lengthen antitumor responses, as well as to widen the utility of PARP inhibitors • Balancing efficacy and toxicities…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.